Receptor Interacting Protein Kinase Pathways Regulate Innate B Cell Developmental Checkpoints But Not Effector Function in Mice.
B cell development and differentiation
B-1 cell development
RIPK1, RIPK3
caspase 8
marginal zone B cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
08
2021
accepted:
22
11
2021
entrez:
27
12
2021
pubmed:
28
12
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Mutations in the scaffolding domain of Receptor Interacting Protein kinases (RIP) underlie the recently described human autoimmune syndrome, CRIA, characterized by lymphadenopathy, splenomegaly, and autoantibody production. While disease mechanisms for CRIA remain undescribed, RIP kinases work together with caspase-8 to regulate cell death, which is critical for normal differentiation of many cell types. Here, we describe a key role for RIP1 in facilitating innate B cell differentiation and subsequent activation. By comparing RIP1, RIP3, and caspase-8 triple deficient and RIP3, caspase-8 double deficient mice, we identified selective contributions of RIP1 to an accumulation of murine splenic Marginal Zone (MZ) B cells and B1-b cells. We used mixed bone-marrow chimeras to determine that innate B cell commitment required B cell-intrinsic RIP1, RIP3, and caspase-8 sufficiency. RIP1 regulated MZ B cell development rather than differentiation and RIP1 mediates its innate immune effects independent of the RIP1 kinase domain. NP-KLH/alum and NP-Ficoll vaccination of mice doubly deficient in both caspase-8 and RIP3 or deficient in all three proteins (RIP3, caspase-8, and RIP1) revealed uniquely delayed T-dependent and T-independent IgG responses, abnormal splenic germinal center architecture, and reduced extrafollicular plasmablast formation compared to WT mice. Thus, RIP kinases and caspase-8 jointly orchestrate B cell fate and delayed effector function through a B cell-intrinsic mechanism.
Identifiants
pubmed: 34956189
doi: 10.3389/fimmu.2021.758407
pmc: PMC8696004
doi:
Substances chimiques
GTPase-Activating Proteins
0
Ralbp1 protein, mouse
0
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
Ripk3 protein, mouse
EC 2.7.11.1
Caspase 8
EC 3.4.22.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758407Subventions
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132798
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001120
Pays : United States
Informations de copyright
Copyright © 2021 Parthasarathy, Hägglöf, Hadley, McLennan, Mattke, Dudley, Kumagai, Dong and Leadbetter.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2004 Sep 1;173(5):2976-84
pubmed: 15322156
J Exp Med. 2000 Oct 16;192(8):1175-82
pubmed: 11034607
Nat Immunol. 2008 Jan;9(1):54-62
pubmed: 18037889
Science. 2018 Aug 24;361(6404):810-813
pubmed: 30026316
Adv Immunol. 2017;134:47-88
pubmed: 28413023
Nat Immunol. 2016 Dec;17(12):1407-1414
pubmed: 27798616
Annu Rev Immunol. 2005;23:161-96
pubmed: 15771569
Immunity. 2006 Jun;24(6):729-739
pubmed: 16782029
J Immunol. 2017 Nov 15;199(10):3387-3394
pubmed: 29109178
Mol Cell Biol. 2004 Feb;24(4):1464-9
pubmed: 14749364
Science. 2001 Sep 14;293(5537):2111-4
pubmed: 11509691
Physiol Rev. 2019 Jan 1;99(1):115-160
pubmed: 30354964
Nat Rev Immunol. 2009 Jul;9(7):491-502
pubmed: 19521398
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7753-8
pubmed: 24821786
Trends Cell Biol. 2017 Nov;27(11):800-809
pubmed: 28642032
Nat Rev Immunol. 2002 May;2(5):323-35
pubmed: 12033738
Immunity. 2001 Aug;15(2):289-302
pubmed: 11520463
Nat Immunol. 2004 Mar;5(3):317-27
pubmed: 14758357
Mol Immunol. 2008 May;45(10):2881-7
pubmed: 18343501
Nature. 2011 Mar 17;471(7338):373-6
pubmed: 21368761
J Exp Med. 2002 Jul 1;196(1):15-26
pubmed: 12093867
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9714-9722
pubmed: 31048504
Curr Opin Immunol. 2008 Dec;20(6):632-8
pubmed: 18848883
Nature. 2011 Mar 17;471(7338):368-72
pubmed: 21368762
Nature. 2019 Nov;575(7784):683-687
pubmed: 31748744
Int Immunol. 1995 Aug;7(8):1213-23
pubmed: 7495728
Cytokine. 2008 Oct;44(1):44-8
pubmed: 18707897
J Immunol. 2005 Sep 15;175(6):3469-73
pubmed: 16148088
Immunol Res. 2011 Dec;51(2-3):227-36
pubmed: 22038529
Cell Death Dis. 2016 Sep 29;7(9):e2379
pubmed: 27685623
J Exp Med. 2005 Sep 19;202(6):727-32
pubmed: 16157684
Cell Death Differ. 2019 Jan;26(1):4-13
pubmed: 30050058
N Engl J Med. 2017 Apr 27;376(17):1615-1626
pubmed: 28445677
Nature. 2011 Mar 17;471(7338):363-7
pubmed: 21368763
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):970-975
pubmed: 30591564
Nat Immunol. 2002 May;3(5):443-50
pubmed: 11967543
J Immunol. 2016 Sep 15;197(6):2063-8
pubmed: 27527595
Nat Immunol. 2011 Nov 27;13(1):44-50
pubmed: 22120118
Front Immunol. 2018 Oct 08;9:2285
pubmed: 30349534
Science. 2005 Mar 4;307(5714):1465-8
pubmed: 15746428
J Exp Med. 2001 Dec 3;194(11):1691-7
pubmed: 11733583
Immunity. 2004 Jun;20(6):785-98
pubmed: 15189742
Immunol Rev. 2017 May;277(1):76-89
pubmed: 28462525
Trends Cell Biol. 2015 Jun;25(6):347-53
pubmed: 25662614
Immunity. 2019 Feb 19;50(2):348-361.e4
pubmed: 30737145
J Exp Med. 2017 Nov 6;214(11):3171-3182
pubmed: 28855241
Nature. 2020 Jan;577(7788):103-108
pubmed: 31827281
Cell Death Differ. 2009 Jan;16(1):3-11
pubmed: 18846107
Nat Immunol. 2015 Jul;16(7):689-97
pubmed: 26086143
Immunity. 2016 Jul 19;45(1):46-59
pubmed: 27396959